Deprecated: Function get_magic_quotes_gpc() is deprecated in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 152

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 469

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 474

Notice: Undefined variable: type in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 560

Notice: Undefined variable: sortString in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 563
MODIFIED FUSION PARTNER

MODIFIED FUSION PARTNER

Brand Owner Address Description
MFP2 Acceptys, Inc. 3960 Broadway New York NY 10032 MODIFIED FUSION PARTNER;Modified Fusion Partner of 2nd Generation, which represents an immortal cell line that can be used to create hybridomas, capable of production a variety of materials, including human proteins, such as antibodies, when fused with antibody producing cells;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.